Summary

Our study uses an extensive, iterative research technique with a deviation minimization focus to produce the most precise estimates and forecasts. The organization divides and estimates quantitative parts of the market using a mix of top-down and bottom-up methodologies. Additionally, data triangulation—which examines the market from three angles—recurs frequently in all of our research studies.

On many fronts, raw market data is gathered and compiled. To make sure that only verified and authenticated sources are taken into consideration, data is constantly vetted. Furthermore, data is extracted from numerous reports within our repository and several well-known commercial databases. Understanding the entire value chain is crucial for a thorough understanding of the market, and we gather information from buyers, distributors, and suppliers of raw materials to make this process easier.

Trade journals, technical symposia, and surveys are good sources for technical concerns and trends. Technical information is also obtained with an emphasis on white space and freedom of movement from an intellectual property standpoint. Additionally gathered are industry factors pertaining to pricing patterns, constraints, and drivers. This means that a variety of original data are included in the material that is produced, and this data is further cross-validated and certified with public sources.
We use simulation models to produce our market estimates and forecasts. A distinct model is built specifically for every investigation. Data is supplied into the model and simultaneously examined for pricing patterns, application development, market dynamics, and technology landscape. These parameters are compared, and time series analysis, regression, and correlation are used to quantify their impact across the predicted period. Market forecasting is carried out using a mix of technical analysis, industry experience, and domain knowledge in addition to economic instruments.

Technological market models are utilized for long-term forecasting, while econometric models are typically employed for short-term forecasting. These are grounded in a combination of corporate principles, regulatory frameworks, economic outlooks, and the state of technology.

Topical Drug Delivery Market Market based on Connectivity Product:
• Semi-Solid Formulations
• Liquid Formulations
Topical Drug Delivery Market Market based on Route Of Administration:
• Dermal
• Ophthalmic
• Nasal
Topical Drug Delivery Market Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The topical drug delivery industry is split into four product categories: transdermal products, liquid formulations, solid formulations, and semi-solid formulations. Because they are easier to use, have less side effects that enhance patient adherence, and can topically deliver a greater range of drug molecules than other formulations, semi-solid formulations account for a sizable portion of the market.

The market is divided into dermal, ocular, rectal, vaginal, and nasal drug delivery segments based on the mode of administration. The numerous benefits of using dermal medication administration, including its ease of use and higher patient compliance for long-term treatment in situations like chronic pain or skin problems, are primarily responsible for its significant market share. Additionally, dermal medications are subject to less regulation than ophthalmic treatments, which facilitates more accessible product introductions and uptake. Consequently, the growth of the category market is anticipated to be improved.

The market is divided into home care settings, hospitals & clinics, burn centers, and other institutions based on the type of facility used. Topical drug delivery systems are becoming more and more popular as point-of-care tools in home care settings as well as an alternate method of drug delivery. This is mostly attributable to increased patient comfort and awareness, which have improved patient acceptability of home care.

North America led the topical drug delivery market in 2021, with shares coming from Europe, Asia Pacific, Latin America, and the Middle East and Africa. The availability of advantageous reimbursement options, rising public awareness of innovative pharmaceutical drug delivery technologies, the execution of pro-business government initiatives, rising affordability and per capita healthcare spending, and the presence of numerous multinational pharmaceutical behemoths are the key factors driving market growth in this region.

Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India) are some of the notable players in the topical drug delivery market.

• This report illustrates the most vital attributes of the Topical Drug Delivery Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Topical Drug Delivery Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Topical Drug Delivery Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Topical Drug Delivery Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Product: Market Size & Analysis
5.1. Overview
5.2. Semi-Solid Formulations
5.3. Liquid Formulations
6. Route Of Administration: Market Size & Analysis
6.1. Overview
6.2. Dermal
6.3. Ophthalmic
6.4. Nasal
7. Geography: Market Size & Analysis
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. Competitive Landscape
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. Vendor Profiles
9.1. HISAMITSU PHARMACEUTICALS
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. BAYER AG
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. NOVARTIS AG
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. GALDERMA HOLDING SA
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. GLAXOSMITHKLINE PLC
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. JOHNSON & JOHNSON PRIVATE LIMITED
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. BAUSCH HEALTH COMPANIES INC.
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. CIPLA LIMITED
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. 3M COMPANY
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. MERCK & CO., INC.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy

10. Analyst Opinion
11. Annexure
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. TOPICAL DRUG DELIVERY MARKET VALUE FOR SEMI-SOLID FORMULATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. TOPICAL DRUG DELIVERY MARKET VALUE FOR LIQUID FORMULATIONS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 5. TOPICAL DRUG DELIVERY MARKET VALUE FOR DERMAL, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. TOPICAL DRUG DELIVERY MARKET VALUE FOR OPHTHALMIC, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. TOPICAL DRUG DELIVERY MARKET VALUE FOR NASAL, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 9. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 10. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 11. U.S TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 12. U.S TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 13. CANADA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. CANADA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 15. MEXICO TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 16. MEXICO TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 17. EUROPE TOPICAL DRUG DELIVERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 18. EUROPE TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 19. EUROPE TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 20. GERMANY TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. GERMANY TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 22. U.K TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. U.K TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 24. FRANCE TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 25. FRANCE TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 26. ITALY TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. ITALY TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 28. SPAIN TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 29. SPAIN TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 30. ROE TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. ROE TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 32. ASIA PACIFIC TOPICAL DRUG DELIVERY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 33. ASIA PACIFIC TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 34. ASIA PACIFIC TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 35. CHINA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. CHINA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 37. INDIA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 38. INDIA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 39. JAPAN TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 40. JAPAN TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 41. REST OF APAC TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. REST OF APAC TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 43. LATIN AMERICA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 44. LATIN AMERICA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 45. BRAZIL TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. BRAZIL TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 47. ARGENTINA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 48. ARGENTINA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 49. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 50. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 51. SAUDI ARABIA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. SAUDI ARABIA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 53. UAE TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 54. UAE TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 55. REST OF MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. REST OF MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD BILLION)
TABLE 57. HISAMITSU PHARMACEUTICALS: FINANCIALS
TABLE 58. HISAMITSU PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 59. HISAMITSU PHARMACEUTICALS: RECENT DEVELOPMENTS
TABLE 60. BAYER AG: FINANCIALS
TABLE 61. BAYER AG: PRODUCTS & SERVICES
TABLE 62. BAYER AG: RECENT DEVELOPMENTS
TABLE 63. NOVARTIS AG: FINANCIALS
TABLE 64. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 65. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 66. GALDERMA HOLDING SA: FINANCIALS
TABLE 67. GALDERMA HOLDING SA: PRODUCTS & SERVICES
TABLE 68. GALDERMA HOLDING SA: RECENT DEVELOPMENTS
TABLE 69. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 70. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 71. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 72. JOHNSON & JOHNSON PRIVATE LIMITED: FINANCIALS
TABLE 73. JOHNSON & JOHNSON PRIVATE LIMITED: PRODUCTS & SERVICES
TABLE 74. JOHNSON & JOHNSON PRIVATE LIMITED: RECENT DEVELOPMENTS
TABLE 75. BAUSCH HEALTH COMPANIES INC.: FINANCIALS
TABLE 76. BAUSCH HEALTH COMPANIES INC.: PRODUCTS & SERVICES
TABLE 77. BAUSCH HEALTH COMPANIES INC.: DEVELOPMENTS
TABLE 78. CIPLA LIMITED: FINANCIALS
TABLE 79. CIPLA LIMITED: PRODUCTS & SERVICES
TABLE 80. CIPLA LIMITED: RECENT DEVELOPMENTS
TABLE 81. 3M COMPANY: FINANCIALS
TABLE 82. 3M COMPANY: PRODUCTS & SERVICES
TABLE 83. 3M COMPANY: RECENT DEVELOPMENTS
TABLE 84. MERCK & CO., INC.: FINANCIALS
TABLE 85. MERCK & CO., INC.: PRODUCTS & SERVICES
TABLE 86. MERCK & CO., INC.: RECENT DEVELOPMENTS